Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2353${count})

  • MJFF Research Grant, 2011
    Caspase- 1 Inhibition to Reduce Cleaved Alpha-synuclein in Pre-clinical Models of Parkinson's Disease

    Objective/Rationale:
    We will test the hypothesis that caspase-1 inhibition will down- regulate α-synuclein (α-SYN) at mRNA and/or protein levels within the SN and restore impaired function of the...

  • Defining Cognitive Phenotypes of Parkinson’s Disease, 2011
    Development of Multimodal Imaging Biomarkers for Cognitive Dysfunction in Parkinson's Disease

    Objective/Rationale:
    By the time a person with Parkinson’s disease (PD) meets diagnostic criteria for dementia, the brain has already been ravaged. Unfortunately, current clinical, neuropsychological...

  • Therapeutics Development Initiative, 2011
    Lead Optimization and Pharmacological Characterization of Selective mGluR3 PAMs as Novel Neuroprotective Agents for Parkinson's Disease

    Objective/Rationale:
    mGluR3 is a novel target that could lead to neuroprotection through production of GDNF and TGF-beta in striatal neurons. The goals of the current project are first to optimize...

  • MJFF Research Grant, 2011
    Alpha-synuclein Expression Lowering therapeutics: Hit Confirmation

    Objective/Rationale:
    Simply increasing dosage of the wild-type alpha-synuclein gene (SNCA) is sufficient to cause dopaminergic neurodegeneration and Parkinson’s disease in rare families carrying an...

  • LRRK2, 2011
    Identification of the LRRK2 Phosphatase

    Objective/Rationale:
    Exactly how Parkinson’s disease (PD) develops is not known, however current research indicates that the leucine rich repeat kinase 2 (LRRK2) protein plays a central role in the...

  • Rapid Response Innovation Awards, 2011
    Use of HspB1 Chaperone to Inhibit Pathological Alpha-synuclein Aggregation

    Objective/Rationale:
    The misfolding and aggregation of the protein alpha-synuclein has been identified as pivotal event causing Parkinson's disease. All cells in our body possess so-called chaperones...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.